57 related articles for article (PubMed ID: 20518808)
1. Oral delivery of mouse [d-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, in male C57BL/6J wild-type and ob/ob mice: effects on energy balance, glycaemic control and serum osteocalcin levels.
Novakovic ZM; Leinung MC; Lee DW; Grasso P
Diabetes Obes Metab; 2010 Jun; 12(6):532-9. PubMed ID: 20518808
[TBL] [Abstract][Full Text] [Related]
2. Oral delivery of mouse [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, in male Swiss Webster mice: a study comparing the pharmacokinetics of oral delivery to intraperitoneal, subcutaneous, intramuscular, and intranasal administration.
Lee DW; Leinung MC; Grasso P
Regul Pept; 2010 Feb; 160(1-3):129-32. PubMed ID: 20026361
[TBL] [Abstract][Full Text] [Related]
3. Intranasal delivery of mouse [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, improves energy balance, glycaemic control, insulin sensitivity and bone formation in leptin-resistant C57BLK/6-m db/db mice.
Waldrop MA; Leinung MC; Lee DW; Grasso P
Diabetes Obes Metab; 2010 Oct; 12(10):871-5. PubMed ID: 20920039
[TBL] [Abstract][Full Text] [Related]
4. The effects of age on uptake, serum half-life and bioavailability of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, in male C57BL/6J mice.
Lee DW; Leinung MC; Grasso P
Regul Pept; 2008 Oct; 150(1-3):62-5. PubMed ID: 18455249
[TBL] [Abstract][Full Text] [Related]
5. [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, augments the effects of orally delivered exenatide and pramlintide acetate on energy balance and glycemic control in insulin-resistant male C57BLK/6-m db/db mice.
Leinung MC; Grasso P
Regul Pept; 2012 Nov; 179(1-3):33-8. PubMed ID: 22960403
[TBL] [Abstract][Full Text] [Related]
6. Intranasal administration of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, enhances total uptake and bioavailability in Swiss Webster mice when compared to intraperitoneal, subcutaneous, and intramuscular delivery systems.
Novakovic ZM; Leinung MC; Lee DW; Grasso P
Regul Pept; 2009 Apr; 154(1-3):107-11. PubMed ID: 19344673
[TBL] [Abstract][Full Text] [Related]
7. Myristic acid conjugation of [D-Leu-4]-OB3, a biologically active leptin-related synthetic peptide amide, significantly improves its pharmacokinetic profile and efficacy.
Novakovic ZM; Anderson BM; Grasso P
Peptides; 2014 Dec; 62():176-82. PubMed ID: 25453979
[TBL] [Abstract][Full Text] [Related]
8. [D-Leu-4]-OB3, an orally bioavailable leptin-related synthetic peptide insulin sensitizer: a study comparing the efficacies of [D-Leu-4]-OB3 and metformin on energy balance and glycemic regulation in insulin-deficient male Swiss Webster mice.
Novakovic ZM; Leinung MC; Grasso P
Peptides; 2013 May; 43():167-73. PubMed ID: 23500518
[TBL] [Abstract][Full Text] [Related]
9. [D-LEU-4]-OB3, a synthetic leptin agonist, improves hyperglycemic control in C57BL/6J ob/ob mice.
Grasso P; Rozhavskaya-Arena M; Leinung MC; Lee DW
Regul Pept; 2001 Sep; 101(1-3):123-9. PubMed ID: 11495687
[TBL] [Abstract][Full Text] [Related]
10. Oral delivery of [D-Leu-4]-OB3 and MA-[D-Leu-4]-OB3, synthetic peptide leptin mimetics: Immunofluorescent localization in the mouse hypothalamus.
Anderson BM; Jacobson L; Novakovic ZM; Grasso P
Brain Res; 2017 Jun; 1664():1-8. PubMed ID: 28347670
[TBL] [Abstract][Full Text] [Related]
11. Design of a synthetic leptin agonist: effects on energy balance, glucose homeostasis, and thermoregulation.
Rozhavskaya-Arena M; Lee DW; Leinung MC; Grasso P
Endocrinology; 2000 Jul; 141(7):2501-7. PubMed ID: 10875251
[TBL] [Abstract][Full Text] [Related]
12. [D-Leu-4]-OB3 and MA-[D-Leu-4]-OB3, small molecule synthetic peptide leptin mimetics, improve glycemic control in diet-induced obese (DIO) mice.
Wang A; Anderson BM; Novakovic ZM; Grasso P
Peptides; 2018 Mar; 101():51-59. PubMed ID: 29269073
[TBL] [Abstract][Full Text] [Related]
13. Substantiation of ovarian effects of leptin by challenging a mouse model of obesity/type 2 diabetes.
Pallares P; Garcia-Fernandez RA; Criado LM; Letelier CA; Fernandez-Toro JM; Esteban D; Flores JM; Gonzalez-Bulnes A
Theriogenology; 2010 May; 73(8):1088-95. PubMed ID: 20172601
[TBL] [Abstract][Full Text] [Related]
14. Intracerebroventricular leptin administration differentially alters cardiac energy metabolism in mice fed a low-fat and high-fat diet.
Keung W; Cadete VJ; Palaniyappan A; Jablonski A; Fischer M; Lopaschuk GD
J Cardiovasc Pharmacol; 2011 Jan; 57(1):103-13. PubMed ID: 20980918
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effects of leptin-related synthetic peptide 116-130 on food intake and body weight gain in female C57BL/6J ob/ob mice may not be mediated by peptide activation of the long isoform of the leptin receptor.
Grasso P; White DW; Tartaglia LA; Leinung MC; Lee DW
Diabetes; 1999 Nov; 48(11):2204-9. PubMed ID: 10535455
[TBL] [Abstract][Full Text] [Related]
16. Temperature dependence of O2 consumption; opposite effects of leptin and etomoxir on respiratory quotient in mice.
Högberg H; Engblom L; Ekdahl A; Lidell V; Walum E; Alberts P
Obesity (Silver Spring); 2006 Apr; 14(4):673-82. PubMed ID: 16741269
[TBL] [Abstract][Full Text] [Related]
17. Leptin deficiency per se dictates body composition and insulin action in ob/ob mice.
van den Hoek AM; Teusink B; Voshol PJ; Havekes LM; Romijn JA; Pijl H
J Neuroendocrinol; 2008 Jan; 20(1):120-7. PubMed ID: 18081560
[TBL] [Abstract][Full Text] [Related]
18. Leptin stimulates fibroblast growth factor 23 expression in bone and suppresses renal 1alpha,25-dihydroxyvitamin D3 synthesis in leptin-deficient mice.
Tsuji K; Maeda T; Kawane T; Matsunuma A; Horiuchi N
J Bone Miner Res; 2010 Aug; 25(8):1711-23. PubMed ID: 20200981
[TBL] [Abstract][Full Text] [Related]
19. Assessing the Safety of MA-[D-Leu-4]-OB3, a Synthetic Peptide Leptin Mimetic: Two Pre-Clinical Toxicity Studies in Male and Female C57BL/6 Mice.
Enemark F; Novakovic ZM; Grasso P
Int J Toxicol; 2023 Dec; 42(6):504-514. PubMed ID: 37556196
[TBL] [Abstract][Full Text] [Related]
20. Oral delivery of octreotide acetate in Intravail® improves uptake, half-life, and bioavailability over subcutaneous administration in male Swiss webster mice.
Maggio ET; Grasso P
Regul Pept; 2011 Apr; 167(2-3):233-8. PubMed ID: 21329733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
